Open-label Extension Trial for Pre- and Postmenopausal Women With HSDD.

Trial Profile

Open-label Extension Trial for Pre- and Postmenopausal Women With HSDD.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Flibanserin (Primary)
  • Indications Decreased libido
  • Focus Adverse reactions; Registrational
  • Sponsors Sprout Pharmaceuticals
  • Most Recent Events

    • 14 Mar 2012 Company (Sprout Pharmaceuticals) added as trial sponsor as reported by ClinicalTrials.gov.
    • 23 Nov 2010 Status changed from recruiting to discontinued according to ClinicalTrials.gov record.
    • 18 Oct 2010 Planned end date changed from 1 Feb 2012 to 1 Jan 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top